Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat in cystic fibrosis (12-week efficacy and 6-month safety)
2010-019802-17Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Tiotropium 5 µg Respimat with Placebo Respimat (2 arms). Primary endpoint: Change from baseline in percent predicted FVC (AUC0-4H) at 12 weeks. Started Jul 2010; status: completed.
02
Drugs
tiotropium
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-019802-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019802-17.